These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 24793135)

  • 1. A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations.
    Kohsaka S; Shukla N; Ameur N; Ito T; Ng CK; Wang L; Lim D; Marchetti A; Viale A; Pirun M; Socci ND; Qin LX; Sciot R; Bridge J; Singer S; Meyers P; Wexler LH; Barr FG; Dogan S; Fletcher JA; Reis-Filho JS; Ladanyi M
    Nat Genet; 2014 Jun; 46(6):595-600. PubMed ID: 24793135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Discovery of a new mutation in MYOD1 characterizes a subset of aggressive embryonal rhabdomyosarcoma partnering with mutations of the PI3K-AKT pathway].
    Orbach D
    Bull Cancer; 2014 Sep; 101(9):776-7. PubMed ID: 25295632
    [No Abstract]   [Full Text] [Related]  

  • 3. Recurrent MYOD1 mutations in pediatric and adult sclerosing and spindle cell rhabdomyosarcomas: evidence for a common pathogenesis.
    Agaram NP; Chen CL; Zhang L; LaQuaglia MP; Wexler L; Antonescu CR
    Genes Chromosomes Cancer; 2014 Sep; 53(9):779-87. PubMed ID: 24824843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transactivating mutation of the MYOD1 gene is a frequent event in adult spindle cell rhabdomyosarcoma.
    Szuhai K; de Jong D; Leung WY; Fletcher CD; Hogendoorn PC
    J Pathol; 2014 Feb; 232(3):300-7. PubMed ID: 24272621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A MYOD1 mutation cooperates with PI3K pathway activation in ERMS.
    Cancer Discov; 2014 Jul; 4(7):OF19. PubMed ID: 25002625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic analysis and preclinical xenograft model development identify potential therapeutic targets for MYOD1-mutant soft-tissue sarcoma of childhood.
    Ting MA; Reuther J; Chandramohan R; Voicu H; Gandhi I; Liu M; Cortes-Santiago N; Foster JH; Hicks J; Nuchtern J; Scollon S; Plon SE; Chintagumpala M; Rainusso N; Roy A; Parsons DW
    J Pathol; 2021 Sep; 255(1):52-61. PubMed ID: 34086347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional impact and targetability of
    Choo F; Odintsov I; Nusser K; Nicholson KS; Davis L; Corless CL; Stork L; Somwar R; Ladanyi M; Davis JL; Davare MA
    Cold Spring Harb Mol Case Stud; 2022 Jan; 8(1):. PubMed ID: 35012940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MYOD1 (L122R) mutations are associated with spindle cell and sclerosing rhabdomyosarcomas with aggressive clinical outcomes.
    Rekhi B; Upadhyay P; Ramteke MP; Dutt A
    Mod Pathol; 2016 Dec; 29(12):1532-1540. PubMed ID: 27562493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrated genetic and epigenetic analysis defines novel molecular subgroups in rhabdomyosarcoma.
    Seki M; Nishimura R; Yoshida K; Shimamura T; Shiraishi Y; Sato Y; Kato M; Chiba K; Tanaka H; Hoshino N; Nagae G; Shiozawa Y; Okuno Y; Hosoi H; Tanaka Y; Okita H; Miyachi M; Souzaki R; Taguchi T; Koh K; Hanada R; Kato K; Nomura Y; Akiyama M; Oka A; Igarashi T; Miyano S; Aburatani H; Hayashi Y; Ogawa S; Takita J
    Nat Commun; 2015 Jul; 6():7557. PubMed ID: 26138366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MYOD1 as a prognostic indicator in rhabdomyosarcoma.
    Ahmed AA; Habeebu S; Farooqi MS; Gamis AS; Gonzalez E; Flatt T; Sherman A; Surrey L; Arnold MA; Conces M; Koo S; Dioufa N; Barr FG; Tsokos MG
    Pediatr Blood Cancer; 2021 Sep; 68(9):e29085. PubMed ID: 33913590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Molecular Study of Pediatric Spindle and Sclerosing Rhabdomyosarcoma: Identification of Novel and Recurrent VGLL2-related Fusions in Infantile Cases.
    Alaggio R; Zhang L; Sung YS; Huang SC; Chen CL; Bisogno G; Zin A; Agaram NP; LaQuaglia MP; Wexler LH; Antonescu CR
    Am J Surg Pathol; 2016 Feb; 40(2):224-35. PubMed ID: 26501226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rhabdomyosarcoma: molecular analysis of Igf2, MyoD1 and Myogenin expression.
    Krskova L; Augustinakova A; Drahokoupilova E; Sumerauer D; Mudry P; Kodet R
    Neoplasma; 2011; 58(5):415-23. PubMed ID: 21744995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methylation alterations of the MyoD1 upstream region are predictive of subclassification of human rhabdomyosarcomas.
    Chen B; Dias P; Jenkins JJ; Savell VH; Parham DM
    Am J Pathol; 1998 Apr; 152(4):1071-9. PubMed ID: 9546368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of the hedgehog pathway confers a poor prognosis in embryonal and fusion gene-negative alveolar rhabdomyosarcoma.
    Zibat A; Missiaglia E; Rosenberger A; Pritchard-Jones K; Shipley J; Hahn H; Fulda S
    Oncogene; 2010 Dec; 29(48):6323-30. PubMed ID: 20818440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First Reported Case of Malignant Ectomesenchymoma with p.Leu122Arg Mutation in MYOD1 Gene: Extensive Intra- and Extracranial Tumor in a 15-Year-Old Female.
    Pena-Burgos EM; De Sabando DP; Utrilla C; Pozo-Kreilinger JJ; Sastre A; Rubio P; Escudero A; Mendiola-Sabio M; Pérez-Martínez A
    Head Neck Pathol; 2023 Sep; 17(3):855-863. PubMed ID: 36913073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting oxidative stress in embryonal rhabdomyosarcoma.
    Chen X; Stewart E; Shelat AA; Qu C; Bahrami A; Hatley M; Wu G; Bradley C; McEvoy J; Pappo A; Spunt S; Valentine MB; Valentine V; Krafcik F; Lang WH; Wierdl M; Tsurkan L; Tolleman V; Federico SM; Morton C; Lu C; Ding L; Easton J; Rusch M; Nagahawatte P; Wang J; Parker M; Wei L; Hedlund E; Finkelstein D; Edmonson M; Shurtleff S; Boggs K; Mulder H; Yergeau D; Skapek S; Hawkins DS; Ramirez N; Potter PM; Sandoval JA; Davidoff AM; Mardis ER; Wilson RK; Zhang J; Downing JR; Dyer MA;
    Cancer Cell; 2013 Dec; 24(6):710-24. PubMed ID: 24332040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of target genes of PAX3-FOXO1 in alveolar rhabdomyosarcoma.
    Ahn EH; Mercado GE; Laé M; Ladanyi M
    Oncol Rep; 2013 Aug; 30(2):968-78. PubMed ID: 23733015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The expanding morphological and genetic spectrum of MYOD1-mutant spindle cell/sclerosing rhabdomyosarcomas: a clinicopathological and molecular comparison of mutated and non-mutated cases.
    Tsai JW; ChangChien YC; Lee JC; Kao YC; Li WS; Liang CW; Liao IC; Chang YM; Wang JC; Tsao CF; Yu SC; Huang HY
    Histopathology; 2019 May; 74(6):933-943. PubMed ID: 30604891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MYOD1-mutant spindle cell and sclerosing rhabdomyosarcoma: an aggressive subtype irrespective of age. A reappraisal for molecular classification and risk stratification.
    Agaram NP; LaQuaglia MP; Alaggio R; Zhang L; Fujisawa Y; Ladanyi M; Wexler LH; Antonescu CR
    Mod Pathol; 2019 Jan; 32(1):27-36. PubMed ID: 30181563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sclerosing rhabdomyosarcoma in adults: report of four cases of a hyalinizing, matrix-rich variant of rhabdomyosarcoma that may be confused with osteosarcoma, chondrosarcoma, or angiosarcoma.
    Folpe AL; McKenney JK; Bridge JA; Weiss SW
    Am J Surg Pathol; 2002 Sep; 26(9):1175-83. PubMed ID: 12218574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.